Immunotherapy Targeting Amyloid-β Peptides in Alzheimer’s Disease
Citable Link (URL):http://resolver.sub.uni-goettingen.de/purl?gs-1/17719
Journal Article (Published version)
First published (peer reviewed)In: Huang, Xudong (Eds.) Huang, Xudong (eds.) (2020): Alzheimer’s Disease: Drug Discovery; Exon Publications
Exon Publications, 2020
Neurodegenerative diseases, in particular Alzheimer’s disease, represent significant unmet medical needs due to a lack of effective therapeutic treatment options and cause a substantial burden for health care systems. Accumulation of β-amyloid peptides within the brain is believed to be an initial trigger of the dis- ease process. In the last 20 years, immunotherapy has emerged as a promising target-directed strategy to develop efficient treatment options with disease-modi- fying potential. Unfortunately, either active vaccination against β-amyloid or its fragments, as well as passive immunization using monoclonal antibodies, have largely failed to show a clinical benefit in a variety of clinical trials. This chapter addresses progress and developments with regard to active and passive immuni- zation against Aβ and summarizes the current state of clinical trials.
These documents are avalilable under the license: